

Applicant: Woodwa  
Serial No.: 09/847,935  
Filed: May 3, 2001  
Page 2 of 14

a therapeutic component in a therapeutically effective amount, and

*B1  
concluded*

an efficacy enhancing component in an effective amount to enhance the pharmacokinetic disposition of the therapeutic component and to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane under physiological conditions, the efficacy enhancing component being present in a complex with the therapeutic component and being selected from the group consisting of anionic polymers, fatty acids, and mixtures thereof, the complex remaining substantially intact in an aqueous environment, each of enhanced effects being relative to the effect obtained with the therapeutic component without the efficacy enhancing component.

*Sub  
C2*

40. (Amended) A composition of claim 39 wherein the quinoxaline component is selected from the group consisting of quinoxaline, (2-imidazolyl-2-ylamino) quinoxaline, 5-bromo-6-(2-imidazolyl-2-ylamino) quinoxaline, and quinoxaline derivatives mixtures thereof.

*B2*

41. (Amended) A composition of claim 36 wherein the therapeutic component is selected from the group consisting of NMDA antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, and mixtures thereof.

43. (Amended) A composition of claim 36 wherein the efficacy enhancing component is selected from the group consisting of

BEST AVAILABLE COPY

Applicant: Woodward  
Serial No.: 09/847,935  
Filed: May 3, 2001  
Page 3 of 14

saturated fatty acids and unsaturated fatty acids, and mixtures thereof.

*B2  
conced.*  
44. (Amended) A composition of claim 36 wherein the efficacy enhancing component comprises a fatty acid with more than 12 carbon atoms per molecule.

45. (Amended) A composition of claim 36 wherein the efficacy enhancing component comprises a docosahexanoic acid.

46. (Amended) A composition of claim 36 wherein the efficacy enhancing component comprises a linolenic acid.

*Sub 3  
B3*  
48. (Amended) A composition of claim 36 wherein the efficacy enhancing component is therapeutically active when complexed with the therapeutic component.

49. (Amended) A composition of claim 36 wherein the efficacy enhancing component is therapeutically active when the efficacy enhancing component is not complexed with the therapeutic component.

*Sub 4  
C4*  
51. (Amended) A composition of claim 36 wherein the efficacy enhancing component comprises a prostanoid.

*B4*  
52. (Amended) A composition of claim 36 wherein  
the therapeutic component comprises a 5-bromo-6-(2-imidazolyl-2-ylamino) quinoxaline,  
the efficacy enhancing component is selected from the group consisting of docosahexanoic acids, linolenic acids, prostanoids, and mixtures thereof; and  
the efficacy enhancing component enhances the movement of the therapeutic component across a biological membrane under physiological conditions.

Applicant: Woodward  
Serial No.: 09/847,935  
Filed: May 3, 2001  
Page 4 of 14

*B4  
cancel*  
53. (Amended) A composition of claim 36 wherein the complex is insoluble.

*Sub  
C5*  
59. (Amended) A composition comprising:  
an adrenergic agonist; and  
a fatty acid selected from the group consisting of  
docosahexanoic acids, linolenic acids, and mixtures thereof,  
wherein the adrenergic agonist is present in a complex with  
the fatty acid, the complex substantially remains intact in an  
aqueous environment.

*B5*  
60. (Amended) A composition comprising a complex and a carrier  
component, the complex comprising:  
a therapeutic component, and  
an efficacy enhancing component,  
wherein the efficacy enhancing component is selected from  
the group consisting of anionic polymers, fatty acids, and  
mixtures thereof, and is present in an amount effective to  
enhance the movement of the therapeutic component across a lipid  
membrane, or a biological membrane under physiological  
conditions, each of the enhanced effects being relative to the  
effect obtained with the therapeutic component without the  
efficacy enhancing component.

*Sub  
C6*  
*B6*  
63. (Amended) A composition of claim 62 wherein the quinoxaline  
component is selected from the group consisting of quinoxaline,  
(2-imidazolyl-2-ylamino) quinoxaline, 5-bromo-6- (2-imidazolyl-2-  
ylamino) quinoxaline, quinoxaline derivatives and mixtures  
thereof.

64. (Amended) The composition of claim 60 wherein the  
therapeutic component is selected from the group consisting of  
NMDA antagonists, antibacterials, antihistamines, decongestants,

**BEST AVAILABLE COPY**